Biotech Values

[jbog]

Credit Suisse reported the following regarding Sanofi:



Lovenox – lost approximately half of US revenues to generic, CFO expects to retain this level (approx 50% of revenues) going forwards. Sanofi still has 67% of enoxaparin volume and feel the market is stable over the past 8 weeks with Sanofi having contracted with 6 of 7 GPOs in the hospital segment (ca 90%). In the retail market, typical generic erosion is occurring. Discounts have also increased.